PharmaShots Weekly Snapshot (April 29-May 03, 2019)


1.AstraZeneca’s Qternmet XR (dapagliflozin, saxagliptin, metformin hydrochloride) Receives FDA’s Approval for Type-2 Diabetes in the US

Published: May 03, 2019 | Tags: AstraZeneca, Qternmet XR, dapagliflozin, saxagliptin, metformin hydrochloride, Receives, FDA, Approval, Type-2 Diabetes, US

2. Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers

Published: May 02, 2019 | Tags: Celgene, Collaborates, Presage, Evaluate, Therapies, CIVO Technology, Multiple Cancers

3.Boehringer Ingelheim Signs a Clinical Research Agreement with Amal for the Evaluation of Combination Therapy to Treat Stage IV Colorectal Cancer

Published: May 02, 2019 | Tags: Boehringer Ingelheim, Signs, Clinical Research Agreement, Amal, Evaluation, Combination Therapy, Stage IV, Colorectal Cancer

4. GSK Reports Results of Trelegy Ellipta in P-III CAPTAIN Study for Asthma

Published: May 02, 2019 | Tags: GSK, Reports, Results, Trelegy Ellipta, P-III, CAPTAIN Study, Asthma

5. AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

Published: May 03, 2019 | Tags: AstraZeneca, Signs, Exclusive, Research, License, Option Agreement, Transgene, Co-develop, Oncolytic Immunotherapies, Invir.IO Platform

6. Sanofi’s Dengvaxia Receives FDA’s Approval to Prevent Dengue in Endemic Region in the US

Published: May 01, 2019 | Tags: Sanofi, Dengvaxia, Receives, FDA, Approval, Prevent, Dengue, Endemic Region, US

7.Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers

Published: May 01, 2019 | Tags:Tmunity, Signs, Exclusive Research Agreement, University of California, Advance, TCR Therapies, Pediatric Cancers

8. Eisai Terminates its Worldwide Development & Commercialization Agreement with Purdue Pharma for Lemborexant

Published: April 30, 2019 | Tags: Eisai, Terminates, Worldwide, Development, Commercialization, Agreement, Purdue Pharma, Lemborexant

9. Medtronic’s Attain Stability Quad MRI SureScan Left Heart Lead Receives FDA’s Approval for Heart Failure

Published: April 30, 2019 | Tags: Medtronic, Attain Stability Quad MRI SureScan Left Heart Lead, Receives, FDA, Approval, Heart Failure

10.Exelixis Initiates P-III COSMIC-313 Study of Triple Combination Therapy for Advanced Renal Cell Carcinoma

Published: May 01, 2019 | Tags: Exelixis, Initiates, P-III, COSMIC-313, Study, Triple Combination Therapy, Advanced, Renal Cell Carcinoma

11. Medtronic Launches Solitaire X Revascularization Device for Acute Ischemic Stroke in the US

Published: April 30, 2019 | Tags: Medtronic, Launches, Solitaire X Revascularization Device, US, Acute Ischemic Stroke

12. AbbVie’s Skyrizi (risankizumab) Receives European Commission’s Approval for Moderate to Severe Plaque Psoriasis

Published: April 30, 2019 | Tags: AbbVie, Skyrizi, risankizumab, Receives, European Commission, Approval, Moderate, Severe, Plaque Psoriasis

13.Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology

Published: April 30, 2019 | Tags: Roche, Spins-Off, Nimble Therapeutics, Commercialize, Drug Development Technology

14. AbbVie’s Mavyret (glecaprevir and pibrentasvir) Receives FDA’s Approval for All Genotypes of Hepatitis C in Pediatric Patients

Published: April 30, 2019 | Tags: AbbVie, Mavyret, glecaprevir, pibrentasvir, Receives, FDA, Approval, All Genotypes, Hepatitis C, Pediatric Patients

15. Vertex’s Kalydeco (ivacaftor) Receives FDA’s Approval for Cystic Fibrosis in Eligible Infants Aged 6 to Less than 12 Months

Published: April 30, 2019 | Tags: Vertex, Kalydeco, ivacaftor, Receives, FDA, Approval, Treat, Cystic Fibrosis, Infants

16.Abbott Reports Results of High Sensitive Troponin-I Blood Test for Risk Assessment of Heart Diseases

Published: April 30, 2019 | Tags: Abbott, Reports, Results, High Sensitive Troponin-I Blood Test, Risk Assessment, Heart Diseases

17.AstraZeneca Collaborates with BenevolentAI to Develop Therapies for Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis

Published: April 30, 2019 | Tags: AstraZeneca, Collaborates, Benevolent AI, Develop, Therapies, Chronic Kidney Disease, Idiopathic Pulmonary Fibrosis

18.Janssen Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Published: April 29, 2019 | Tags: Janssen, Collaborates, Iktos, Artificial Intelligence, Technology

19. ViiV Healthcare Files NDA for Cabotegravir + Edurant (rilpivirine) to the US FDA to Treat HIV-1 Infection in Adults

Published: April 30, 2019 | Tags: ViiV Healthcare, Files, NDA, Application, FDA, HIV-1, Infection, Adults

20.Sandoz Signs an Agreement with EirGenix to Commercialize Proposed Trastuzumab Biosimilar for HER2+ Cancer Tumors

Published: April 30, 2019 | Tags: Sandoz, Signs, Agreement, EirGenix, Commercialize, Proposed Trastuzumab Biosimilar, HER2+, Cancer Tumors

21.Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) Receives CHMP’s Positive Opinion to Treat Hemophilia A in Adolescents and Adults

Published: April 26, 2019 | Tags: Novo Nordisk, Esperoct, turoctocog alfa pegol, N8-GP, Receives, CHMP, Positive Opinion, Treat, Hemophilia A, Adolescents, Adults

22. Acutus Medical’s AcQMap Contact Mapping Software Receives CE Mark Approval

Published: April 26, 2019 | Tags: Acutus Medical, AcQMap Contact Mapping Software, Receives, CE Mark Approval, EU

23. Sanofi and Lexicon’s Zynquista (sotagliflozin) Receive EU’s MAA to Treat Type-1 Diabetes in Adults

Published: April 26, 2019 | Tags: Sanofi, Lexicon, Zynquista, sotagliflozin, Receive, EU, MAA, Treat, Type-1, Diabetes, Adults

24.AstraZeneca and Merck’s Lynparza (olaparib) Receive CHMP’s Positive Opinion for 1L Maintenance Treatment of BRCA-Mutated Advanced Ovarian Cancer

Published: April 29, 2019 | Tags: AstraZeneca, Merck, Lynparza, olaparib, Receive, CHMP, Positive Opinion, 1L, Treatment, BRCA-Mutated, Advanced, Ovarian Cancer

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post